<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225585</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00104214</org_study_id>
    <nct_id>NCT04225585</nct_id>
  </id_info>
  <brief_title>Persistent Post-Mastectomy Pain: Targeted Pain Coping Skills Training</brief_title>
  <official_title>Persistent Post-Mastectomy Pain: Randomized Clinical Trial of Targeted Pain Coping Skills Training (Targeted-PCST) With Mediational Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test a skills training program to help with coping skills for
      pain that was designed specifically for women with persistent pain after breast cancer
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent pain following breast cancer surgery is increasingly recognized as an important
      clinical and public health issue due to the large number of women affected, the powerful
      negative impact that persistent pain has on emotional and physical functioning and its
      financial costs. Most of the more than a quarter of a million women newly diagnosed with
      breast cancer in the U.S. this year will undergo surgery as a part of curative treatment. The
      prevalence of persistent pain following surgical removal of the affected breast (mastectomy)
      or more limited surgeries (lumpectomy) is high, ranging from 25-60% across studies. Unlike
      acute post-operative pain, which is a normal response to surgical trauma, persistent pain at
      or near the surgical site has an uncertain multifaceted etiology, and no satisfactory
      pharmacological treatment. A critical question is whether key pain-related psychosocial
      factors are drivers of the continuing burden of persistent pain, and whether they could be
      ameliorated by non-pharmacological intervention. The research planned under this award will
      provide a first critical test of the hypothesized driving role of pain catastrophizing in
      persistent pain after breast cancer surgery. It also will explore the role of two other key
      psychosocial variables that may contribute to the burden associated with persistent pain
      after breast cancer surgery: self-efficacy for engaging in valued activities and
      psychological inflexibility. We have developed, manualized, and pilot tested a pain coping
      skills training intervention that specifically targets the needs of women with persistent
      pain following breast cancer surgery (Targeted PCST) and aims to reduce pain catastrophizing,
      increase self-efficacy for engaging in valued activities, and decrease psychological
      inflexibility. We propose a multiple-site, randomized clinical trial to evaluate the efficacy
      of the Targeted-PCST intervention. The study will be conducted in 9 diverse oncology clinics:
      5 affiliated with Duke University/Duke Cancer Network and 4 affiliated with the University of
      Pittsburgh/UPMC Hillman Cancer Center. Participants (N=564) will be randomized to either
      receive: 1) Targeted-PCST, 2) a general health education intervention (control), or 3) usual
      care (control). Participants will complete assessments pre-intervention and at 3 months
      (post-intervention), 6 months follow-up, and 12 months follow-up. Study aims are: Aim1:
      Examine the impact of Targeted-PCST on persistent post-surgical pain severity and
      interference (i.e., PEG score), emotional distress (anxiety and depression), and
      cancer-specific distress. Aim 2: Investigate the impact of Targeted-PCST on pain
      catastrophizing, pain self-efficacy, and psychological inflexibility, and evaluate these
      variables as possible mediators of the benefits of Targeted-PCST. Aim 3: Evaluate the impact
      of Targeted-PCST on pain sensitivity and central sensitization, and explore whether changes
      in these variables mediate group differences in pain severity and interference.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Study staff conducting assessments will be blind to group assignment. To maintain blinding, we will use the following approaches: 1) all study staff will be trained on the importance of blinding and study procedures to maintain blinding; 2) participants will be provided with the rationale and instructions not to disclose their group assignment; 3) the study staff who conduct post-intervention assessments will not be given information about group assignment prior to the assessment; and 4) if a breach occurs, it will be documented and the participant will complete their assessment with a new assessor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PEG Pain Severity and Interference</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Persistent post-surgical pain burden 3-item measure: average pain intensity (P); interference with enjoyment in life (E); interference with general activity (G)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire Depression Screener (PHQ-9)</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>9-item assessment of depressive symptoms over the past two weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Event Scale (IES)</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>15-item measure of intrusive and avoidant cognition regarding breast cancer during the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>13-item assessment of the degree to which participants experience catastrophic thinking during painful experiences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance and Action Questionnaire (AAQ-II)</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>7-item questionnaire designed to measure psychological inflexibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Sensitization Inventory (CSI)</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>25-item questionnaire designed to measure hypersensitivity to senses and signs of central sensitization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain sensitivity: Pressure pain thresholds</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Designed to measure central hyperexcitability using a digital pressure algometer measured pressure that is first perceived as painful and recorded in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central sensitization: Temporal summation</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Designed to measure central pain mediation using weighted pinprick probes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generalized Anxiety Disorder Screener (GAD-7)</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>7-item assessment of symptoms of anxiety over the past two weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Pain Self-Efficacy Scale: Function Self-Efficacy Subscale (FSE)</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>9-item questionnaire designed to measure chronic pain patients' perceived self-efficacy for engaging in activities</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient Healthcare Utilization</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>6-item self-report of time spent utilizing healthcare in the past 4 weeks, as well as medication use and time spent on the intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Five-level EuroQoL-5 Dimensions (5L EQ-5D)</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>5-item assessment of current health utility, plus 0 to 100 rating of overall health; QALYS will be derived from utility estimates</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Targeted Pain Coping Skills Training</condition>
  <condition>General Health Education</condition>
  <condition>Usual Care</condition>
  <arm_group>
    <arm_group_label>Targeted Pain Coping Skills Training (Targeted-PCST)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>novel pain coping skills training intervention designed specifically for women with persistent pain (PP) following breast cancer surgery (active intervention group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>General health education</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>general health education Intervention (control group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual health care and usual medical treatment for pain</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Targeted-PCST</intervention_name>
    <description>skills training and experiential learning exercises</description>
    <arm_group_label>Targeted Pain Coping Skills Training (Targeted-PCST)</arm_group_label>
    <other_name>Targeted Pain Coping Skills Training</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>General health education</intervention_name>
    <description>general health education intervention that focuses on improving overall health</description>
    <arm_group_label>General health education</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  prior diagnosis of Stage 0 to III breast cancer

          -  received first breast cancer surgery (total or partial mastectomy, lumpectomy) in the
             past 3 to 12 months

          -  reports average breast pain of â‰¥3 in the past month on the 0 to 10 pain severity scale

          -  able to speak and read English

          -  able to provide meaningful consent

        Exclusion Criteria:

          -  &lt;18 years of age

          -  history of prior breast surgery

          -  hearing impairment that limits use of videoconferencing for intervention sessions

          -  cognitive impairment that is documented in the medical record or results in being
             unable to provide meaningful consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Shelby, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dana Bovbjerg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Shelby, PhD</last_name>
    <phone>919-416-3410</phone>
    <email>rebecca.shelby@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana Bovbjerg, PhD</last_name>
    <phone>412-623-5965</phone>
    <email>bovbjergdh@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rebecca Shelby, PhD</last_name>
      <phone>919-416-3410</phone>
      <email>rebecca.shelby@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Shelby, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dana Bovbjerg, PhD</last_name>
      <phone>412-623-5965</phone>
      <email>bovbjergdh@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Dana Bovbjerg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

